BELITE BIO, INC
Business
BELITE BIO, INC is a clinical-stage biopharmaceutical company engaged in research and development of novel small-molecule therapeutics targeting degenerative retinal diseases. Its main product candidates include Tinlarebant (LBS-008), an oral RBP4 antagonist in clinical development for Stargardt disease type 1 (STGD1) and geographic atrophy (GA), and LBS-009, an oral RBP4-modulating compound in preclinical development for metabolic diseases such as NAFLD, NASH and type 2 diabetes. The company operates research, development and clinical trial functions and relies on contract research organizations and contract manufacturers for studies and supply. It conducts and sponsors clinical trials and regulatory interactions across the United States, Europe, Japan, China, Taiwan, Australia and other international markets.
Summary from filing dated 2025-03-17
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-77.61M |
| Total assets | $780.56M |
| Total liabilities | $10.07M |
| Stockholders' equity | $770.49M |
| Operating cash flow | $-36.99M |